This journal is not listed in the SCIE, SSCI, AHCI, ESCI, Scopus or JCR 2024 lists. That does not make it unreliable, but check its indexing, peer review and fees carefully.
How to spot predatory journals →01Impact factor
Impact factor of Immuno-Oncology Technology (2026)
The impact factor shown here is the 2-year mean citedness: citations received in a year by the papers Immuno-Oncology Technology published in the two previous years, divided by the number of those papers. That is the same formula as the Journal Impact Factor, calculated by ScholarsColab. The journal is not listed in JCR 2024, so it has no official Journal Impact Factor from Clarivate; the value above is how often its recent papers are cited.
Quartile of Immuno-Oncology Technology
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Immuno-Oncology Technology is not listed in JCR 2024, so it has no JCR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Citations and papers per year
Open access (listed in DOAJ); article processing charge listed at about US$3,340.
Is your paper a fit for Immuno-Oncology Technology?
Most desk rejections come from a scope mismatch. Compare your title and abstract with what this journal really publishes. Free, no sign-up, about 2 minutes.
Check my paper for this journalOr find journals that fit my paper
APC waivers and discounts for Immuno-Oncology Technology APC about US$3,340
No published waiver policy found for its publisher. Ask the editorial office, and compare publishers that do waive the APC.
02Funders
Who funds research published in Immuno-Oncology Technology
Funders named most often
A high share of funded papers usually means the journal is a common choice for grant-supported work in its field. If your funder pays article processing charges, or your country qualifies for a waiver, check what applies to your author team with the free APC waiver checker.
03Indexing
Indexing of Immuno-Oncology Technology
| List | Status |
|---|---|
| Science Citation Index Expanded (SCIE) | Not listed |
| Social Sciences Citation Index (SSCI) | Not listed |
| Arts & Humanities Citation Index (AHCI) | Not listed |
| Emerging Sources Citation Index (ESCI) | Not listed |
| Scopus | Not listed |
| Journal Citation Reports 2024 | Not listed |
From the indexing lists used on ScholarsColab, updated 1 March 2026. Indexing can change: confirm on the Web of Science Master Journal List or the Scopus source list before submitting. Official Journal Impact Factors and JCR quartiles are published by Clarivate; the impact factor on this page is calculated by ScholarsColab (see how the impact factor works).
Each link opens the official record for this journal, searched by its ISSN where we have one.
04How to submit
How to submit to Immuno-Oncology Technology
- Read the guide for authors. It sets the article types, word limit, reference style and file format that Immuno-Oncology Technology accepts. Open the official guide for authors and submit from the same page.
- Format to the journal's style. Check whether it wants a Word file, a LaTeX file or a PDF for the first submission, and follow its reference style; many journals accept any clear format at first and ask for their style only after acceptance.
- Check the fit. Compare your title and abstract with the papers it has published; papers outside the scope are the most common reason for a desk rejection. The Journal Finder shows journals that published the closest work.
- Plan the fee. Immuno-Oncology Technology is fully open access, with an article fee of about US$3,340 after acceptance. See whether your author team qualifies for a waiver with the free APC waiver checker.
- Check your manuscript before you submit. The free Submission Readiness Check asks the seven questions our reviewers ask in every audit and takes about 2 minutes.
05What it publishes
What Immuno-Oncology Technology publishes: real papers
06Published papers
Papers published in Immuno-Oncology Technology
Papers from the publication records ScholarsColab tracks, with their year and citations. Author names are not shown.
- Immuno-Oncology Technology20190 citations
07Reviewer comments
Reviewer comments and rejection reasons for Immuno-Oncology Technology
No reviewer or editor comments have been shared for this journal yet. Did you submit here? Help other researchers by sharing the comments you received, anonymously.
Share reviewer comments for this journal →Across the reviewer comments researchers have shared with us, the points raised most often are figures, tables and equations (21%), literature and references (12%) and novelty and contribution (10%). Before you submit to Immuno-Oncology Technology, a Manuscript Audit by a PhD reviewer in your area checks your paper against exactly these points.
Audit my paper before I submit →Worried about the English? Manuscript editing by editors in your subject: see the price →
Not sure yet? Check if your paper is ready for this journal: free, no AI, under 5 secondsIs Immuno-Oncology Technology right for your paper? Find the right journal
Paste your title, keywords or abstract. See the journals that published the closest papers, with indexing, impact factor, review time and APC.
No AI or language model is used. Your words are matched against the titles of 157,115 real published journal papers, by our mentors and by other researchers (shown without names); journals are ranked by how many closely matching papers they published. Indexing comes from the SCIE, SSCI, AHCI, ESCI, Scopus and JCR 2024 lists, matched by journal name; the impact factor is calculated by ScholarsColab, not the official Clarivate value, and no quartile is shown until the official JCR or SJR quartile can be; review time is the median days from submission to acceptance (not every publisher publishes these dates). Always check a journal’s scope and current indexing before submitting.
08Questions
Frequently asked questions
What is the impact factor of Immuno-Oncology Technology?
Based on ScholarsColab citation data (October 2026), the 2-year impact factor of Immuno-Oncology Technology is 0.47: papers it published in the two previous years were cited 0.47 times on average in a year. The journal is not listed in JCR 2024, so it has no official Clarivate Journal Impact Factor.
What is the h-index of Immuno-Oncology Technology?
The h-index of Immuno-Oncology Technology is 23 (October 2026): 23 of its papers have each been cited at least 23 times. Its i10-index is 53.
What is the APC of Immuno-Oncology Technology?
The listed article processing charge (APC) is about US$3,340 for Immuno-Oncology Technology, an open access journal (data from October 2026). APCs change and can differ by article type, country or discounts, so confirm the current charge on the journal’s website before submitting.
What is the quartile of Immuno-Oncology Technology?
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Immuno-Oncology Technology is not listed in JCR 2024, so it has no JCR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Is Immuno-Oncology Technology indexed in Scopus?
Immuno-Oncology Technology is not listed in the Scopus list, according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Immuno-Oncology Technology an SCIE journal?
Immuno-Oncology Technology is not listed in SCIE or the other Web of Science indexes, according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Immuno-Oncology Technology in Journal Citation Reports (JCR)?
Immuno-Oncology Technology is not listed in the JCR 2024 list, according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
How many papers published in Immuno-Oncology Technology does ScholarsColab track?
We track 1 paper published in Immuno-Oncology Technology in 2019, cited 0 times in total, with a median of 0 citations per paper.
Who funds research published in Immuno-Oncology Technology?
20% of 200 recent research articles in Immuno-Oncology Technology name a funder; the funders named most often are National Health and Medical Research Council, Horizon 2020 Framework Programme, Bristol-Myers Squibb Company.
Popular journals
- The Lancet
- Nature
- Science
- PLoS ONE
- Scientific Reports
- Journal of the American Chemical Society
- Journal of Hepatology
- Remote Sensing
- Journal of Materials Science
- European Heart Journal
- Journal of Clinical Oncology
- Physical Review
- Heliyon
- American Journal of Cardiology
- Electrochimica Acta
- Langmuir
- Journal of Hazardous Materials
- Tetrahedron
- Journal of Organometallic Chemistry
- Electronics Letters
Browse all journals: indexing, impact factor and reviewer comments →